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Abstract
Background: MCF-10A, immortalized but non-transformed human breast epithelial cells, are widely used in
research examining carcinogenesis. The studies presented here were initiated with the observation that MCF-10A
cells left in continuous culture for prolonged periods without re-feeding were prone to the development of
transformed foci. We hypothesized that the depletion of labile culture components led to the onset of processes
culminating in the observed cell transformation. The purpose of this study was to define the factors which
promoted transformation of this cell line.
Results: Changes in levels of phenol red (PHR), hydrocortisone (HC), and epidermal growth factor (EGF) with or
without estrogen treatment indicated that both oxidative stress- and estrogen receptor alpha (ERa)-mediated
pathways contribute to cell transformation. Gene array and Western blotting analyses of cells maintained in our
laboratory and of those from other sources documented detectable ERa and ERbeta (ERb) in this ERa-negative
cataloged cell line. Results also indicate the possibility of a direct association of EGF receptor (EGFR) and ERa in
these cells as well as the formation and high induction of a novel ternary complex that includes ERb (ERa/ERb/
EGFR) in cells grown under conditions facilitating transformation.
Conclusions: Our studies resulted in the development of a growth protocol where the effects of chronic,
physiologically relevant alterations in the microenvironment on cellular transformation were examined. From our
results, we were able to propose a model of transformation within the MCF-10A cell line in which oxidative stress,
ER and EGFR play essential roles. Overall, our work indicates that the immediate microenvironment of cells exerts
powerful growth cues which ultimately determine their transformation potential.
Background
Breast cancer is one of the most common malignancies
affecting women in Western countries [1]. Despite
extensive research efforts worldwide at understanding
and eradicating breast cancer, the cellular processes that
lead to the onset of mammary carcinogenesis have yet
to be definitively elucidated. Oxidative stress has come
under increasing scrutiny in recent years as a causative
factor in mammary carcinogenesis. Chronic infection
and inflammation, which lead to reactive oxygen species
(ROS) generation, are recognized risk factors for cancer
development [2]. 17b-Estradiol (E2) [3-6] and epidermal
growth factor (EGF) [7,8], two agents that can increase
intracellular oxidative stress, are also strongly linked to
the development of breast cancer. E2 binding to estro-
gen receptor (ER) [9-11] and EGF’s known properties as
a growth factor, [1,12] as well as its putative role in
modulating ER expression [13,14], could also lead to cell
transformation through the induction of cellular prolif-
erative responses.
Epidemiological evidence and the recognized risk fac-
tors implicate estrogens as important etiological agents
in the development of breast cancer [9,15-20]. The exact
mechanism(s) by which estrogen contributes to the
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development of breast cancer has not yet been eluci-
dated. Most studies to date have focused on estrogen’s
role as a promoter of carcinogenesis based on its proven
mitogenic activity in cells [9,10,21]. Receptor-based
increases in cell proliferation due to estrogen binding
are thought to act by either increasing spontaneous
errors that make target tissues more susceptible to
initiation or enhancing the replication of clones of
already initiated target cells [10]. Increasingly, however,
the notion that estrogen can function as an initiator of
breast cancer via ROS generation and consequent oxida-
tive DNA damage is gaining experimental support
[3-5,21-24].
Over two decades ago, J. Liehr and coworkers ele-
gantly demonstrated that while 17b-estradiol (E2) expo-
sure induces renal clear-cell carcinoma in Syrian
hamsters, 2-fluoroestradiol (2-Fl-E2), a fluorinated estro-
gen analog that is a potent estrogen but displays
reduced metabolic conversion to catechol estrogen
metabolites, was non-carcinogenic in this system
[25,26]. Oxidation of cytochrome P450-catalyzed cate-
chol estrogen (CE) metabolites, particularly 4-hydroxyes-
tradiol (4-OH-E2), to semiquinones and quinones and
their redox cycling, is thought to generate free radicals
which can effect oxidative DNA damage [22,23,27,28]
leading to mutations and carcinogenesis. 4-OH-E2 is the
predominant catechol formed in human mammary
fibroadenomas and adenocarcinomas tested [29]. The
localized occurrence of a specific estrogen 4-hydroxylase
(CYP1B1) in human breast cancer cells, uterine myoma,
and rodent target organs of estrogen-induced carcino-
genesis has also been observed [29]. Further, formation
of 8-hydroxy-2’-deoxyguanosin (8-OHdG) was higher in
ERa-positive cultured human breast cancer cells and tis-
sues in comparison to ERa-negative cells [30]. Studies
conducted with human sperm and lymphocytes pro-
vided evidence that exposure to various estrogenic com-
pounds can lead to free radical-mediated damage as
well. This damage was diminished in nearly all cases by
catalase, indicating that estrogen-mediated effects act
via hydrogen peroxide (H2O2) production [31].
ERa levels can be modulated by EGF [13,14], which
was shown to increase oxidative DNA damage in mam-
mary tumor cells coincident with increased malignancy
[7]. EGF, a growth factor regulating the proliferation
and differentiation of human mammary epithelial cells,
is thought to be involved in the pathophysiology of
breast cancer [1,12]. Underscoring its significance in
mammary carcinogenesis, EGF is present in several
human breast cancer cell lines and in 15-30% of human
primary invasive breast carcinomas; its mRNA is ele-
vated in ERa-positive human breast cancer cell lines
and tumors, and its expression correlates with poor
prognosis in breast cancer patients [1]. EGF by itself can
increase H2O2 levels [7,8] and, thus, may be a critical
factor in oxidative stress-induced breast cancer.
The culture medium of MCF-10A cells is usually sup-
plemented with various factors such as hydrocortisone
(HC), EGF, and phenol red (PHR, a pH indicator),
which can affect redox state as well as ER activity. We
observed in this study that MCF-10A cells left in contin-
uous culture for prolonged periods without re-feeding
were prone to the development of morphologically
transformed foci. Our hypothesis was that the depletion
of labile culture components induced oxidative stress
and led to the onset of spontaneous transformation.
However, deliberate manipulation of culture compo-
nents and treatment with redox active and inactive
estrogens indicated both oxidative stress- and ERa-
mediated pathways to be operative in the spontaneous
transformation of these cells. While MCF-10A cells are
characterized as ERa-negative, gene array and western
blotting analyses of cells maintained in our laboratory as
well as of those obtained from a variety of different
sources provided documentation of detectable ERa and
ERbeta (ERb) in this cell line. Western blotting analysis
also indicated for the first time the possibility of a direct
association of epidermal growth factor receptor (EGFR)
and ERa in the MCF-10A cell line as well as the forma-
tion and high induction of a novel ternary complex that
includes ERb (ERa/ERb/EGFR) in MCF-10A cells grown
under conditions facilitating their transformation.
Materials and methods
A. Cells and Materials
MCF-10A cells were purchased from American Type
Culture Collection (ATCC; Manassas, VA). MCF-10A
cells were also kindly provided by Drs. J.D. Yager
(Department of Environmental Health Science, The
Johns Hopkins University Bloomberg School of Public
Health, Baltimore, MD; Source #1), K. Eckert (Gittlen
Cancer Research Institute, Penn State College of Medi-
cine, Hershey, PA; Source #2), M. Planas-Silva (Depart-
ment of Pharmacology, Penn State College of Medicine,
Hershey, PA; Source #3), and M. F. Verderame (Depart-
ment of Medicine, Penn State College of Medicine, Her-
shey, PA; Source #4). The laboratories at Penn State
University that kindly provided MCF-10A cells had
obtained these cells independently of one another from
different sources. A custom formulation of PHR-free
Dulbecco’s Modified Eagle’s Medium/Nutrient F12
(DMEM/F12) cell culture medium D231SA, trypsin
(0.25%, 1×), trypsin-ethylenediaminetetraacetic acid
(trypsin-EDTA; 0.05% trypsin, 0.53 mM EDTA, 1×),
L-glutamine (200 mM, 100×), and antibiotic/antimycotic
(100×) solutions were purchased from Atlanta Biologi-
cals (Norcross, GA). Horse serum (HS) was purchased
from Invitrogen (Carlsbad, CA). EGF was purchased
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from R&D Systems (Minneapolis, MN). Protease inhibi-
tor cocktail tablets were obtained from Roche Molecular
Biochemicals (Indianapolis, IN). All other reagents were
purchased as described in the text or from Sigma Che-
mical Company (St. Louis, MO).
B. Cell Culture
MCF-10A cells were maintained in PHR-free DMEM/
F12 culture medium unless otherwise specified. Medium
was supplemented with NaHCO3 (1200 mg/L), CaCl2
(1.05 mM), 5% HS, insulin (10 μg/ml), L-glutamine
(2 mM), antibiotic/antimycotic mixture (1%), EGF
(20 ng/ml), HC (500 ng/ml), and cholera toxin (100 ng/
ml). Cells were fed twice a week and grown to conflu-
ence before subculturing. Briefly, cells were washed
once with Dulbecco’s Phosphate Buffered Saline
(D-PBS) and exposed to trypsin for 15-20 minutes
before the action of trypsin was stopped with 20% HS-
supplemented medium. Cells were then centrifuged at
100 × g in a tabletop centrifuge for 5 min and the cell
pellet was resuspended in medium and transferred to
other flasks. All cells were grown in a single chamber
water-jacketed humidified incubator and maintained in
a 37°C, 5% carbon dioxide (CO2) atmosphere. The num-
ber of passages cells have been propagated in a particu-
lar type of medium is indicated in parentheses next to
the description of the medium [(i.e. -HC/-EGF (#10)]
C. Assay for Morphologic Transformation
MCF-10A cells maintained in PHR-free 5% HS-supple-
mented, HC and EGF-containing [+HC/+EGF (+/+)]
DMEM/F12 medium were subsequently grown for the
5-week morphologic transformation assay in +/+, -HC/-
EGF (-/-), -HC/+EGF (-/+), or +HC/-EGF (+/-) DMEM/
F12 media supplemented with 0.5% HS and 240 μg
bovine serum albumin (BSA)/ml in the absence or pre-
sence of PHR. Cells in these eight medium groups were
non-treated (NT) or treated with 0.01% ethanol (EtOH)
alone or with 0.01% EtOH solution of 1 nM E2 or 1 nM
2-fluorestradiol (2-Fl-E2). Initially, cells were either left
untreated or treated with appropriate agents and then
plated in triplicate in 6-well plates at a density of 5 ×
105 cells/well. Thereafter, cells were maintained in con-
tinuous culture for 6 weeks, refed and re-treated once a
week, and examined microscopically each week for signs
of contact-uninhibited growth and the appearance of
morphologically transformed foci. Transformed foci
were counted once a week from 1-5 weeks at 4× magni-
fication as they appeared along two perpendicular lines
intersecting in the center of each well. To assess the
reversibility of phenotypic cell alterations, after five
weeks, PHR, HC, and EGF were added back singly or
together, to cultures that were lacking these factors, and
the number of transformed foci was again determined at
week 6. The assay was performed once with duplicates
of each treatment analyzed. Some treated cells were pla-
ted in poly-D-lysine-coated tissue-culture plates in an
attempt to increase detailed microscopic visualization
and examination of foci.
D. Western Immunoblotting Analysis
Cells used for Western blot analysis included MCF-10A
cells (non-treated and treated under various treatment
protocols and media conditions) as well as MCF-10A
cells acquired from different laboratories and grown in
-PHR, 5% HS, +/+ medium. Total cell extracts were
obtained by first trypsinizing and pelleting cells as
described in section B of Materials and Methods and
washing once with D-PBS. Cell lysis buffer [5.0 M
EDTA, 150 mM NaCl, 50 mM Tris HCl, 1% Triton X-
100, 1% SDS, 50 mM dithiothreitol (DTT), and protease
inhibitor cocktail tablets (1 tablet per 10 ml buffer)] was
added to each tube at 100 μl buffer per 1 × 106 cells
and mixed well to lyse the cells completely. Lysates
were transferred to microcentrifuge tubes, incubated on
ice for 10-30 min., and centrifuged at 12,000 × g in a
microcentrifuge at 4°C for 15 min. The supernatants
were collected and stored at -80°C for subsequent ana-
lyses. Alternately, Pierce (Rockford, IL) NE-PER Nuclear
and Cytoplasmic Extraction Reagents were used as per
the manufacturer’s protocol for the stepwise separation
and preparation of cytoplasmic and nuclear extracts.
Protein content was measured using Bradford Reagent.
Proteins (25-30 μg) were resolved by SDS-PAGE in 12%
SDS-Tris-HCl polyacrylamide mini-running gels and
transferred onto nitrocellulose membranes (BioRad
Laboratories; Hercules, CA). Membranes were incubated
with primary antibodies to ERa, ERb, or EGFR at a
dilution of 1:1000 in 5% non-fat dry milk-Tris Buffered
Saline/Tween (TBS/T) buffer at 4°C overnight, followed
by incubation with both the appropriate horseradish
peroxidase (HRP)-conjugated secondary antibody at a
dilution of 1:10,000 and anti-biotin antibody at 1:1000
dilution in 5% non-fat dry milk in TBS/T at room tem-
perature (RT) for 1 h. Protein was detected using the
Western Lightning Chemiluminescent Reagent Plus Kit
from PerkinElmer (Wellesley, MA) as per the manufac-
turer’s directions. Antibodies (Ab) and controls used
were: ERa (62A3) mouse monoclonal Ab, EGFR rabbit
polyclonal Ab, and anti-biotin Ab (Cell Signaling Tech-
nology; Beverly, MA); ERb (PA1-313) rabbit Ab,
human, recombinant ERa RP-310 and ERb (long
form) RP-312 (Affinity BioReagents; Golden, CO);
EGF-stimulated A431 cell lysate (Upstate Biotechnol-
ogy; Lake Placid, NY). Peroxidase-conjugated Immuno-
pure goat anti-mouse and sheep anti-rabbit IgG’s were
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used as secondary antibodies (Pierce Chemical Com-
pany, Rockford, IL)
E. Gene Expression Analysis of the Human Toxicity/Stress
and Estrogen Signaling Pathways
Cells were trypsinized and pelleted according to the pro-
tocol outlined in Section B, and RNA was isolated from
cells using the RNAqueous RNA isolation system
(Ambion, Inc.; Austin, TX) according to the manufac-
turer’s protocol. Immediately afterwards, contaminating
DNA was removed using Ambion’s “DNA-free” DNase
Treatment and Removal Reagents again as per the man-
ufacturer’s directions. The RNA supernatants were
transferred to new RNAse-free tubes and stored at
-80C. Prior to use in gene expression studies, the con-
centration and purity of RNA was determined by ali-
quoting a small amount of the samples in HPLC-grade,
RNase-free dH2O and measuring absorbance at 260 nm
and 280 nm. RNA concentration was calculated using a
value of 1A260 nm = 40 μg RNA/ml. and its purity
assessed by confirming that the ratio of A260/A280 was
near 2.0. Nonrad-GEArray Kit Pathway Specific Gene
Expression Profiling System (SuperArray, Inc; Bethesda,
MD) was used for the analysis of gene expression after
RNA isolation. The detailed manufacturer’s protocol
was followed for analysis. Briefly, biotinylated cDNA
probes were synthesized from 5-10 μg total RNA by
reverse transcription using a PCR thermal cycler and
SuperArray reagents. Afterwards, cDNA probes were
hybridized using a mini hybridization incubator kit
reagents to pathway-specific gene expression array
membranes (either human toxicity/stress or estrogen
signaling) provided by the manufacturer. Finally, mem-
branes were incubated with alkaline phosphatase (AP)-
streptavidin, and chemiluminescent detection was per-
formed with the provided CDP-Star substrate and
immediate exposure to x-ray film between 0-5 min.
Signal intensities were quantitated (semi-log) using
UN-SCAN-IT digitizing software (Silk Scientific; Orem,
UT) after the x-ray films were scanned onto a computer.
Sample signal intensities were normalized against a
housekeeping gene’s signal intensities. Each membrane
contained two spots for each cDNA analyzed. Means of
the intensity (in pixels) of the duplicate spots were used
for analysis
F. Statistical Analysis
Significance of differences between two groups was
assessed using one-tailed Student’s “t” test assuming
unequal variances. One-way ANOVA followed by Dun-
net’s test was utilized to compare all groups to a control
group, while One-way ANOVA followed by Tukey’s test
was used to compare all groups to each other. For all
tests, p < 0.05 was considered significant.
Results
1. Simultaneous depletion of HC, EGF, and PHR from
culture medium is necessary for the morphologic
transformation of MCF-10A cells
MCF-10A cells were grown for 5 weeks in continuous
culture in 6-well tissue culture plates in PHR-containing
or PHR-free medium lacking either one, both, or none
of the factors HC and EGF. Cells in these four types of
media were also exposed once a week to either 1 nM E2
or 1 nM 2-Fl-E2 in 0.01% EtOH, or just 0.01% ethanol
(EtOH) as a control. Within five days in culture, cells
grown in the presence of EGF [+HC/+EGF (+/+) and
-HC/+EGF (-/+)] became confluent, whereas those
grown in the absence of EGF [-HC/-EGF (-/-) and
+HC/-EGF (+/-)] displayed a slower growth rate. Cells
in the +/- medium exhibited the lowest proliferative
capacity. Transformed-looking foci were noted to first
appear after 13 days in culture and only in PHR-free -/-
cultures (Fig. 1e-f). After 5 weeks, large, prominent foci
became apparent but again, only in PHR-free -/- cul-
tures (Fig. 2e-f). The average number of foci per well of
a 6-well tissue culture plate was significantly elevated to
79.5+6.50 (p < 0.0005) in -/- medium versus 0 in media
containing either HC or EGF (Table 1). An important
outcome of these experiments was the observation that
the presence of PHR inhibits the appearance of trans-
formed foci (Figs. 1 &2; Table 1). To verify that the
piled cells observed in Figs. 1 and 2 were live cells and
rule out the possibility of artifactual observation, MCF-
10A cells seeded in triplicate at a density of 6.25 × 104
cells/well in PHR-containing or -deficient -/- medium
for 3 weeks in 6-well tissue culture plates were stained
with neutral red (10 μg/ml) and photographed. Trans-
formed foci in PHR-deficient -/- medium as well as the
monolayer underneath were stained red, confirming the
viability of cells both in foci and monolayer (Fig. 3b).
The fact that foci were stained deep red while the
monolayer was light red suggests piling of cells in foci
and proves that foci being observed were not artifacts.
Cultures grown in PHR-containing -/- medium did not
form foci, as demonstrated by the absence of darkly
stained piles of cells (Fig. 3a).
2. b-Estradiol (E2) elevates the morphologic
transformation of MCF-10A cells in -HC/-EGF (-/-) medium,
whereas 2-Fl-E2 does not
In an attempt to correlate the transformative and oxida-
tive capacities of E2 within human breast epithelial cells,
the MCF-10A cell line was exposed to 1 nM E2 within
the four media types already discussed (+HC/+EGF,
-HC/-EGF, -HC/+EGF, and +HC/-EGF). In addition,
cells cultured in -/- growth medium were also treated
with 2-Fl-E2 to assess the transforming potential of a
non-redox cycling estrogen. +/+, -/+, and +/- cultures
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were already shown to be resistant to transformation,
since E2 treatment of these cultures did not induce
transformation (Figs. 1 & 2; Table 1) within the five-
week treatment protocol. However, transformed foci
appeared in E2-treated -/- cultures starting from 13
days of exposure (Fig. 1f). Although at 13 days, foci aris-
ing in E2-treated cells were light and less prominent
(Fig. 1f) than in non-treated cultures (Fig 1e), by 5
weeks the foci in E2-treated cultures were much denser
and larger in size (Fig. 2) than they were at 13 days.
While foci sizes in the non-treated cells were still larger
in comparison to the E2-treated cultures (Fig. 2e-f) even
at 5 weeks, E2 treatment resulted in more numerous
foci (Table 1), by over 2-fold in PHR-free -/- cultures in
comparison to non-treated controls (p < 0.0005). In
contrast to E2, exposure of cells to 2-Fl-E2 in -/- med-
ium did not lead to the appearance of transformed foci
at 13 days (data not shown). However, at 5 weeks, trans-
formed foci did appear in 2-Fl-E2-treated -/- cultures
within certain wells and/or areas of wells where cellular
degradation was apparent (Fig. 4b). In wells/areas of
apparent healthy cell growth in 2-Fl-E2-treated cultures,
  (a) (b) (c)
(d) (e) (f)
 (g) (h) (i)
(j) (k) (l)







Figure 1 Effects of PHR, HC, EGF, and E2 on Focus Formation by MCF-10A Cells Cultured for 13 Days. MCF-10A cells, plated at 5 × 105
cells/well, were grown in 6-well tissue culture plates under differing culture and treatment (once a week) conditions and photographed at low
magnification (phase contrast; 4×) to enable visual indication of the number of transformed foci after13 days in culture. Photographs are
representatives of triplicate samples from one experiment.
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no foci were discernable (Fig. 4a). In contrast, E2-induced
foci in -/- cultures formed uniformly among and within
wells irrespective of cellular disintegration (Fig. 2f). None-
theless, the apparently transformed foci in 2-Fl-E2-treated
cultures were counted and the total foci number was used
as a reliable comparative indicator of transformation
potential among treatments. After five weeks of growth,
E2 significantly (p < 0.0005) enhanced the transformation
of MCF-10A cells in -/- medium in comparison to con-
trols, whereas 2-Fl-E2 was unable to increase the basal
transformation rate, as evidenced by the formation of a
lower number of foci than in controls (Table 1). E2-treated
cells formed over five times the number of foci as EtOH
controls in -/- medium (Table 1).
3. Re-introduction of HC, but not PHR or EGF,
to -PHR/-HC/-EGF MCF-10A cultures after 5 weeks can
partially reverse morphologic transformation
To evaluate whether microenvironmental changes
induce irreversible morphologic transformation of MCF-
10A cells, PHR, HC, or EGF alone as well as HC and
EGF together were re-introduced to -PHR/-HC/-EGF
culture medium after the formation of foci in 5 weeks.
Microscopic evaluation after 6 weeks revealed no
   (a) (b) (c)
(d)       (e) (f)
   (g) (h) (i)
(j) (k) (l)







Figure 2 Effects of PHR, HC, EGF, and E2 on Focus Formation by MCF-10A Cells Grown in Continuous Culture for 5 Weeks. MCF-10A
cells, plated at 5 × 105 cells/well, were grown in 6-well plates under differing culture and treatment (once a week) conditions and
photographed (phase contrast; 10×) after 5 weeks in continuous culture. Photographs are representatives of triplicate samples from one
experiment.
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obvious changes aside from indications of slightly smal-
ler foci in cultures where either HC or EGF was added
(data not shown). Importantly, only the addition of HC
induced a partial (~40%) but significant (p < 0.01)
decrease in foci numbers (Table 2). Adding back EGF,
by itself or with HC, resulted only in a non significant
increase in the number of foci.
4. MCF-10A transformed foci exhibit extensive
interconnections while displaying varying morphologies
depending on the growth condition
Slight microenvironmental alterations were seen to pro-
foundly affect the morphology and growth characteris-
tics of MCF-10A human breast epithelial cells. An
intriguing characteristic of foci noted in this cell line
was the appearance, once foci began to form, of exten-
sive interconnections among them, forming a lattice-like
network (Fig. 5a-c). To enable more detailed visualiza-
tion of transformed foci, 10 nM E2-treated MCF-10A
cells were grown in -/- medium until foci formed, tryp-
sinized, and re-plated in poly-d-lysine culture flasks.
After 50 days, foci photographed at 40× magnification
enabled the identification of a somewhat polarized egg-
shaped structure with a distinct, prominent membrane,
perhaps of more than one layer, containing the growing
contact uninhibited cells within its boundary (Fig. 5d).
Growth characteristics of MCF-10A cells grown in the
three different types of medium (+/+, -/-, -/+) were
examined. Five passages after reaching confluence in
their respective medium type, differences among the
cells became apparent. Figure 6 shows subconfluent cul-
tures of +/+, -/- (passage #11), and -/+ (passage #13)
cells 24 hours after plating. In contrast to +/+ cells,
which exhibit normal subconfluent epithelial growth
Table 1 Effects of PHR, HC, EGF, E2, and 2-Fl-E2 on the
Appearance of Transformed Foci in MCF-10A Cells after
5 Weeks in Continuous Culture
Treatments Number of Foci/Well
(+HC/+EGF) +PHR 0.00
(+HC/+EGF) -PHR 0.00
(+HC/+EGF) -PHR; 1 nM E2 0.00
(-HC/-EGF) +PHR 0.00
(-HC/-EGF) -PHR 79.50 +/- 6.50*, #
(-HC/-EGF) -PHR; 0.01% EtOH 33.50 +/- 27.50
(-HC/-EGF) -PHR; 1 nM E2 182.00 +/- 2.00**,F
(-HC/-EGF) -PHR; 1 nM 2-Fl-E2 19.00 +/- 5.00*
(-HC/+EGF) +PHR 0.00
(-HC/+EGF) -PHR 0.00
(-HC/+EGF) -PHR; 1 nM E2 0.00
(+HC/-EGF) +PHR 0.00
(+HC/-EGF) -PHR 0.00
(+HC/-EGF) -PHR; 1 nM E2 0.00
Effects of PHR, HC, EGF, E2, and 2-Fl-E2 on the appearance of transformed foci
in MCF-10A cells after 5 weeks in continuous culture. MCF-10A cells, plated at
5 × 105 cells/well, were exposed to different culture and treatment conditions
for 5 weeks in continuous culture. Cells were maintained and treated once a
week in 6-well TC plates. The average number of transformed foci/well that
appeared at 5 weeks in triplicate wells of each culture/treatment type from
one experiment was used for analysis. Significance of differences was
analyzed using One-way ANOVA followed by either Dunnet’s or Tukey’s test.
Using One-way ANOVA followed by Dunnet’s test:
-HC/-EGF/-PHR/E2 vs -HC/-EGF/-PHR/EtOH **p < 0.0005
-HC/-EGF/-PHR vs -HC/-EGF/-PHR/EtOH *p < 0.05
Using One-way ANOVA followed by Tukey’s test:
-HC/-EGF/-PHR/E2 vs all groups Fp < 0.0005
-HC/-EGF/-PHR vs all groups except -HC/-EGF/-PHR/EtOH #p < 0.0005
(a) -HC/-EGF; +PHR (b) -HC/-EGF; -PHR
Figure 3 Effect of PHR Presence in -HC/-EGF Medium on the Appearance of MCF-10A Transformed Foci After 3 Weeks of Continuous
Culture. MCF-10A cells were seeded in triplicate at a density of 6.25 × 104 cells/well in 6-well tissue culture plates and grown in -HC/-EGF
medium either with or without phenol red for 3 weeks in continuous culture. Cells were stained with neutral red (10 mg/ml) and photographed
(10× obj.). Photographs are representatives of triplicate wells per culture condition from one experiment.
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(Fig 6a), -/- cultures already show the presence of small
foci growing atop clusters of monolayer cell growth (Fig.
6b). Extensions among foci at this time have already
begun to form. MCF-10A -/+ cultures did not form foci
at this early time, but displayed a unique morphology of
extended, fibroblast-like cells with respect to the other
two types of cultures (Fig 6c). Therefore, even a slight
microenvironmental alteration can profoundly affect the
growth characteristics of human breast epithelial cells,
with serious implications regarding their transformation
potential.
5. MCF-10A cells exhibit detectable levels of both ERa
and ERb gene expression
The necessity for PHR depletion in our studies indicated
a need for ERa-mediated events in the transformation of
(a) (b)
Figure 4 Effects of 1 nM 2-Fl-E2 Treatment on Focus Formation
by MCF-10A Cells Grown in Continuous Culture for 5 Weeks.
MCF-10A cells, plated at 5 × 105 cells/well, were grown in 6-well TC
plates in -PHR/-HC/-EGF medium and treated with 1 nM 2-Fl-E2
once a week. Two different areas of one well were photographed
(phase contrast; 10×) in order to show variations in cell morphology
and focus formation within the same treatment group at 5 weeks in
continuous culture. Photographs are representatives of triplicate
samples from one experiment.
Table 2 Reversibility of Morphologic Transformation due
to Re-addition of PHR, HC, and/or EGF to MCF-10A Cells
Grown for 5 Weeks in -PHR/-HC/-EGF Medium
Group Culture Condition Mean Number of Foci/Well +/- SE
1 -PHR/-HC/-EGF 153.50 +/- 0.50
Add Back PHR 157.50 +/- 4.50
2 -PHR/-HC/-EGF 125.67 +/- 4.98
Add Back HC 75.33 +/- 6.74*
3 -PHR/-HC/-EGF 79.50 +/- 6.50
Add Back EGF 92.50 +/- 12.50
4 -PHR/-HC/-EGF 145.50 +/- 12.00
Add Back HC & EGF 156.50 +/- 12.50
MCF-10A cells, plated at 5 × 105 cells/well, were grown in -PHR/-HC/-EGF
medium for 5 weeks in 6-well tissue culture plates, at which time cells were
re-exposed to depleted agents once for 1 week. Foci were counted at weeks
5 and 6 and the average number of foci/well in 2 wells per re-added agent(s)
before and after re-supplementation from one experiment was used to assess
reversibility of morphologic transformation. Significance was analyzed using
One-way ANOVA followed by Tukey’s test.
Add Back HC vs -PHR/-HC/-EGF *p < 0.01
(a) -HC/-EGF; EtOH/DMSO (b) -HC/-EGF; EtOH/DMSO
      (0.01%); 11d; 20x         (0.01%); 11d; 4x
(c) -HC/-EGF; 0.1 nM E2;   (d) -HC/-EGF; 10 nM E2; 
      11d; 20x 
             in poly-d-lysine (50d); 40x
Figure 5 Morphology of MCF-10A Transformed Foci. MCF-10A
transformed foci, which appear under different culture/treatment
conditions, were photographed to document morphologic
characteristics. The photograph for panel (d) was taken from a
single T25 flask from one experiment. All other photographs are
representatives of triplicate wells of 6-well tissue culture plates from
one experiment.
(a) +HC/+EGF; 10x (b) -HC/-EGF #11; 10x 
(c) -HC/+EGF #13; 10x 
Figure 6 Effect of HC and/or EGF Withdrawal on MCF-10A Cell
Growth and Morphology in PHR-Free Medium after 24 h
Culture. MCF-10A cells were either maintained in fully
supplemented medium (+HC/+EGF), grown in HC/EGF-depleted
medium (-HC/-EGF) for 11 passages, or grown in HC-deficient
medium (-HC/+EGF) for 13 passages. Cells grown in different media
types were photographed under phase-contrast microscopy 24
hours after plating. Photographs are representatives of triplicate
samples of each culture condition from one experiment.
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MCF-10A cells. PHR’s known weak estrogenicity and
binding to ERa [32,33] may suppress receptor’s binding
of E2, thereby preventing the relatively more potent hor-
monal and/or oxidative properties of E2 from effecting
transformation. Although this cell line is categorized as
ERa-negative, our results made it necessary to re-exam-
ine the ERa status of these cells. A commercially avail-
able gene expression array kit (SuperArray; Bethesda,
MD) was utilized for the analysis of human estrogen sig-
naling pathway gene expression in non-treated and
1 nM E2-treated (twice a week for 2 weeks) MCF-10A
cells grown under various media conditions. Table 3
demonstrates detectable gene expression of both ERa
and ERb among the different growth and treatment con-
ditions for MCF-10A cells assessed. ERa gene expres-
sion was consistently higher in comparison to ERb
expression levels. Although no indicative trends and/or
upregulation in ER expression due to varying treatments
and culture conditions was noted, the data demonstrate
persistent, detectable levels, particularly of ERa gene
expression, in this cell line.
6. Western blotting confirms the presence of ERa and
ERb in MCF-10A cells; Possibility of a direct association of
ERa and EGFR, with induction of a putative ternary
complex composed of ERa/ERb/EGFR in those cells that
are the most prone to transformation
MCF-10A cells maintained in different growth condi-
tions and those acquired from various laboratories were
subjected to Western blotting analysis for ERa, ERb,
and EGFR expression (Fig. 7). Nuclear extracts from 16
samples containing 42 μg protein were electrophoresed
onto two 12% SDS-Tris-HCl polyacrylamide gels (gel 1:
Fig. 7a, c, e & gel 2: Fig. 7b, d, f) and transferred to
nitrocellulose membranes. The two membranes were
then probed consecutively with antibodies directed
against ERa (Fig. 7a &7b), ERb (Fig. 7c &7d) and EGFR
(Fig. 7e &7f). The first three lanes of both gels contain,
respectively, control human recombinant proteins ERa
and ERb from baculovirus-infected Sf9 cells, and total
cell lysate from EGF-stimulated A431 cells (positive
control for EGFR) (Fig. 7a-f; lanes 1-3 & 9-11). All other
lanes contain MCF-10A sample nuclear extracts. Mem-
branes were first probed with antibodies directed against
ERa, which detect a 66 kD protein. These blots are
depicted in Figure 7a-b and appear to show very light
but detectable bands at 66 kD in all MCF-10A sample
lanes (Fig. 7a-b; lanes 4-8 & 12-16) corresponding to
ERa, as corroborated by staining in this region in the
ERa positive control (Fig. 7a-b; lanes 1 & 9). Bands are
absent in the lane containing recombinant ERb protein
(Fig. 7a-b; lanes 2 & 10), verifying the absence of non-
specific binding. Interestingly, EGFR control cell extracts
from A431 cells also appear to indicate the presence of
even lighter, but still detectable bands at 66 kD (Fig. 7a-
b; lanes 3 & 11). A431 are not known to express ERa,
but such a possibility is suggested by observed growth
inhibition by the antiestrogen tamoxifen [34] and
growth stimulation by the estrogenic compound genis-
tein [35] in A431 cells. The same two membranes were
re-probed with antibodies directed against ERb (Fig. 7c-
d). Bands around 60 kD appear to be present in the lane
containing the recombinant ERb (Fig. 7c-d; lanes 2 &
10), which has a molecular weight of 59.2, and in all
other MCF-10A samples tested (Fig. 7c-d; lanes 4-8 &
12-16). Bands are not present in the lane containing
recombinant ERa (Fig. 7c-d; lanes 1 & 9), again con-
firming the absence of non-specific antibody binding.
A431 control cell extracts do not show the presence of
ERb (Fig. 7c-d, lanes 3 & 11) as they did ERa (Fig. 7a-b;
lanes 3 & 11). Re-probing the gels with antibodies direc-
ted against EGFR (Fig. 7e-f), which detect the protein at
~175 kD, indicates the presence of bands between 140
and 200 kD, again in all MCF-10A samples (Fig. 7e-f;
lanes 4-8 & 12-16) and in the EGF-stimulated A431 cell
extracts (Fig. 7e-f; lanes 3 & 11), which serve as a posi-
tive control for EGFR. Bands are not seen in lanes con-
taining human recombinant ERa (Fig. 7e-f; lanes 1 & 9)
or ERb (Fig. 7e-f; lanes 2 & 10). These data taken
together appear to confirm the presence of ERa, ERb,
and EGFR in all MCF-10A samples tested, even in those
obtained from different laboratories, and suggest the
possible presence of ERa in the human squamous cell
carcinoma line A431. What is even more intriguing in
these Western blots is the presence of a band at
Table 3 Estrogen Receptor Gene Expression in MCF-10A







1 +HC/+EGF; NT 62.75 9.86
-HC/+EGF (#21); NT 57.98 5.88
2 +HC/+EGF; NT 59.79 15.82
-HC/-EGF (#1); 1 nM E2 57.48 10.21
3 -HC/-EGF (#1); NT 50.77 a
-HC/-EGF (#1); 1 nM E2 53.96 a
ER gene expression in MCF-10A cells maintained in and exposed to various
culture/treatment conditions was assessed using a human estrogen signaling
pathway-specific gene expression profiling system (SuperArray, Inc; Bethesda,
MD) as described in the Methods section. Results shown are those of three
different experiments comparing two different culture conditions at a time
and using 5-10 μg total RNA. MCF-10A cells grown in culture media either
containing or lacking HC/EGF were either left non-treated (NT) or treated
twice a week with 1 nM E2 for 2 weeks. Numbers in parentheses indicate the
number of passages in that particular medium type. Mean signal intensity
(pixels × 10-4) values from duplicate spots of both ERa and ERb per
membrane were normalized against those of a housekeeping gene and taken
to be representative of mean gene expression.
a) Signal too weak to evaluate
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~200 kD in all MCF-10A samples and A431 samples that
is detected by antibodies directed against both EGFR and
ERa (Fig. 7a-b &7e-f; lanes 3-8 & 11-16). This band
appears to be induced in MCF-10A cells grown for 28 pas-
sages in HC- and EGF-depleted medium (Fig. 7a & e; lane
6). This band is not seen only in the photograph (Fig. 7f,
lane 12), but is present as an extremely faint band in the
original x-ray film of the newly acquired MCF-10A cells
grown in +/+ medium. While highly speculative, an asso-
ciation between EGFR and ERa in both MCF-10A and
A431 cells, which is upregulated in MCF-10A -/- #28 cells
is one possible explanation for these results. Interestingly,
in blots which were analyzed with ERb antibodies (Fig. 7c-
d), this ~200 kD band is apparent only in A431 (Fig. 7c-d;
lanes 3 & 11), MCF-10A -/- #28 (Fig. 7c; lane 6), and
MCF-10A -/+ #71 (Fig. 7c; lane 8) cells. Again, one possi-
ble explanation for this, which will need to be explored
further in order to be confirmed, is the existence of a tern-
ary association of ERa/ERb/EGFR unique to these particu-
lar cells. The absence of detectable ERb at ~60 kD (Fig.
7c-d; lanes 3 & 11) in A431 cells may be an indication of
low levels of ERb in these cells which preferentially associ-
ate with EGFR/ERa complex. Overall, however, Western
blot analysis appeared to demonstrate detectable levels of
ERa, ERb, and EGFR in MCF-10A cells grown under var-
ious culture conditions in our lab and those obtained from
a variety of sources. These data also initiate speculation of
a direct association of EGFR and ERa in MCF-10A cells.
Figure 7 Analysis of MCF-10A Cells for ERa, ERb, and EGFR. Nuclear proteins extracted from MCF-10A cells that were exposed to differing
culture conditions were analyzed by Western blotting for the presence of ERa, ERb, and EGFR. Numbers in parentheses indicate the number of
passages in that particular type of medium. Proteins (42 μg/lane) were electrophoresed onto two 12% Tris-HCl gels (lanes 1-8 and 9-16
respectively) and transferred onto nitrocellulose membranes. Membranes were probed with antibodies directed against ERa (a and b), stripped
and re-probed with antibodies directed against ERb (c and d), and stripped a second time and re-probed with antibodies directed against EGFR
(e and f). Results shown are those from one experiment.
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MCF-10A cells grown long-term in HC/EGF-depleted
medium (-/- #28) appear to display a high induction of
this complex but with the added presence of ERb. This
putative ternary complex is also slightly induced in MCF-
10A cells chronically depleted of HC and propagated for a
longer time (-/+ #71), presented in lane 8.
7. Modulation of ER-responsive genes in MCF-10A cells
by E2 and redox manipulation
In support of the role of an active ERa component in
MCF-10A cell transformation, Table 4 demonstrates
that 1 nM E2 treatment of -/- MCF-10A cultures upre-
gulated prolactin (PRL) gene expression by over 6-fold,
which was statistically significant (p< 0.05), while it
down-regulated progesterone receptor (PR) gene expres-
sion by over 2-fold, suggesting hormonal estrogen
responsiveness of this cell line. PRL gene expression was
also seen to be modulated in the presence of EGF by
the long-term depletion of HC, where -/+ (#21) MCF-
10A cells exhibited a decrease in PRL gene expression
by 4-fold (p < 0.05) in comparison to +/+ cultures
(Table 5). Expression of several other genes involved in
the estrogen signaling pathway was also modulated in
response to the chronic depletion of HC from MCF-
10A culture medium (Table 5). Expression of the genes
c-fos and c-jun was diminished by nearly 2- and over 3-
fold, respectively, while c-myc expression was abrogated
entirely. ER-binding fragment-associated antigen9
(EBAG9) and EGF gene expression were downregulated
by over 4-fold each, while H-ras by 3-fold.
Discussion
The mandatory depletion of HC, a potent anti-inflam-
matory agent thought to decrease oxidative stress in
cells, in order to transform cells suggests that an oxidant
milieu is critical to the carcinogenic process (Figs. 1 &2).
However, re-addition of HC, significantly (p < 0.01), but
only partially, reversed the morphologic transformation
seen in 5-week -/- MCF-10A continuous cultures
(Table 2). The inhibitory effect of added HC on cell
transformation and the reversible nature of its action
have been documented in various cell types [36-38]. For
example, the presence of HC reversibly mediated growth
inhibition as well as anchorage-dependence of rat C6
glioma cells and blocked colony formation in agarose
[36,37]. HC-mediated ROS suppression [39,40], decrease
of nuclear NF-B [41], and increases in antioxidant
enzymes [42] are likely responsible for such transforma-
tion-retarding effects.
Transformation of MCF-10A cells, however, was also
dependent on the simultaneous depletion of EGF from
the culture medium (Figs. 1 &2); hence, EGF withdra-
wal-mediated ROS generation could play a role in such
transformation. In mouse proximal tubular (MPT) cells,
EGF deprivation was shown to elevate cellular superox-
ide anion radical levels and induce apoptosis [43]. How-
ever, by itself, EGF can trigger H2O2 production [7,8]
and thus, the finding that its presence inhibits transfor-
mation supports the possible outgrowth of EGF-inde-
pendent clones and suppression of EGFR activity as
important events in the transformation pathway [44,45]
as well. In fact, adding back EGF, both by itself or with
HC resulted in a slight increase in the number of foci
(Table 2) and points to the possible outgrowth of
Table 4 Comparison of Progesterone Receptor and
Prolactin Gene Expression in 1 nM E2-Treated versus
Non-treated MCF-10A -HC/-EGF (#1) Cells






1 PR 5.17 2.27
2 PRL 0.82 5.52 *
MCF-10A cells maintained in +HC/+EGF medium were grown for 1 passage in
-HC/-EGF medium and either left not treated (NT) or were treated twice a
week for 2 weeks with 1 nM E2. Gene expression analysis of genes involved
in the human estrogen signaling pathway in MCF-10A cells grown under
these two treatment conditions were compared using a gene expression
profiling system (SuperArray, Inc; Bethesda, MD) as described in the Methods
section. Mean signal intensity (pixels × 10-4) values from duplicate spots of
each cDNA per membrane were normalized against those of a housekeeping
gene and taken to be representative of mean gene expression. Results shown
are those of one experiment comparing two different treatment conditions.
Significance of differences between expression of PR and PRL genes in MCF-
10A -HC/-EGF (1 nM E2) cultures versus expression of their respective controls
in MCF-10A -HC/-EGF (NT) cultures was analyzed using one-tailed Student’s “t”
test assuming unequal variances. *p < 0.05
Table 5 Comparison of Estrogen Signaling Pathway Gene
Expression in MCF-10A -HC/+EGF (#21) versus +HC/+EGF
Cells






1 c-fos 22.50 +/- 4.70 12.36 +/- 3.37
2 c-jun 11.87 +/- 2.78 3.83 +/- 2.20
3 c-myc 2.20 +/- 0.03 0.00 +/- 0.00**
4 EBAG9 8.11 +/- 3.2 1.82 +/- 0.79
5 EGF 8.05 +/- 2.98 2.08 +/- 0.25
6 H-ras 6.75 +/- 1.35 1.95 +/- 1.85
7 PRL 32.19 +/- 2.42 8.57 +/- 0.16*
8 pS2 1.16 +/- 0.91 3.73 +/- 1.84
MCF-10A cells maintained in +HC/+EGF medium were either kept in this
medium or subsequently grown for 21 passages in -HC/+EGF medium. Gene
expression analysis of genes involved in the estrogen signaling pathway in
MCF-10A cells grown in these two media types were compared using a gene
expression profiling system (SuperArray, Inc; Bethesda, MD) as described in
the Methods section. Mean signal intensity (Pixels × 10-4) values from
duplicate spots of each cDNA per membrane were normalized against those
of a housekeeping gene and taken to be representative of mean gene
expression. Results shown are those of one experiment comparing two
different culture conditions. Significance of differences between expression of
each gene in MCF-10A -HC/+EGF #21 cultures versus expression of its
respective control in MCF-10A +HC/+EGF cultures was analyzed using one-
tailed Student’s “t” test assuming unequal variances. *p < 0.05, **p < 0.005
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EGF-autonomous cells, which then become hypersensi-
tive to the action of EGF perhaps due to the acquisition
of a constitutively active EGFR pathway. Lack of EGF in
cell culture medium has previously been linked to the
spontaneous transformation of HMT-3522 cells [46,47],
to carcinogen-initiated neoplastic transformation of Syr-
ian golden hamster pancreatic duct cells [48], and to
benzo[a]-pyrene (BP)-enhanced cell proliferation in
MCF-10A cells [49].
Our studies showed that transformation rates of MCF-
10A cells treated with 1 nM E2 were elevated by over
5-fold in comparison to those of EtOH controls, only
within a pre-existing oxidant microenvironment gener-
ated by HC and, possibly, EGF depletion (Table 1). The
probability that E2-mediated transformation relies on
the generation of ROS is indicated by the observation
that 1 nM 2-Fl-E2, an estrogen whose metabolism leads
to the formation of lower levels of oxidants [4,25-27,50],
is incapable of increasing transformation in MCF-10A
cells over EtOH controls (Table 1). Studies previously
conducted in animals and in various cell models impli-
cate estrogens in transformation, ROS generation,
and oxidative DNA damage, particularly 8-OHdG
[25,28,30-32,51,52]. Yet, our data also implicated estro-
gen receptor-mediated effects on cellular transformation.
MCF-10A cells exposed to E2 are refractory to transfor-
mation even in the absence of HC (-/+ cultures) but in
the presence of EGF (Figs. 1 &2; Table 1), implying a
need for the possible upregulation of ER-a, due to EGF
withdrawal, within the carcinogenic process in this
model. Low EGF concentrations in a low serum-
containing medium stimulated growth of high ERa-
expressing human breast cancer cell lines A431 and
BT20, while high EGF doses inhibited their growth [53].
Taken together, the data implicate EGF independence
and E2-generated ROS and/or ERa-mediated events as
possible contributors to MCF-10A transformation.
The presence of ERa in this ERa-negative categorized
cell line and its importance in transformation is under-
scored by observed transformation suppression in the
presence of PHR (Figure 3; Table 1) at 5 days (data not
shown), 13 days (Fig. 1), and 5 weeks (Fig. 2). PHR, a
known weak estrogen [32,33] used as a pH indicator at
a concentration of 15-45 μM in most tissue culture
media, can bind to the ERa of MCF-7 human breast
cancer cells at an affinity of 0.001% of E2 and was seen
to reduce ERa-mediated growth stimulatory processes
of exogenous estrogens [32]. The PHR concentration of
media used in the present study (21.5 μM) could, there-
fore, effectively have blocked E2-mediated hormonal
and/or oxidative effects on foci formation, as was
observed. MCF-10A cells are normally cultured in med-
ium supplemented with horse serum (HS), which con-
tains estradiol. It is possible that chronic exposure of
MCF-10A cells to picomolar (~6 × 10-12 M) estradiol
contained in HS led to upregulated ERa expression and
contributed in part to the transformation of MCF-10A
cells seen in -/- medium even in the absence of added
E2 (NT and ethanol controls). We found that ERa-
mediated events in MCF-10A cell transformation most
likely constitute irreversible alterations since re-introdu-
cing PHR to culture medium had no effect on the num-
ber of foci, once formed (Table 2).
Gene expression arrays confirmed the expression of
both ERa and ERb in MCF-10A cells (Table 3) as well
as estrogen responsive genes (Tables 4 &5). The persis-
tent, detectable levels of ERa and ERb observed among
varying culture conditions and treatments (Table 3),
even in cells newly purchased from ATCC, provide evi-
dence contradicting the classification of the MCF-10A
cell line as ERa-negative. Hormonal estrogen respon-
siveness was also indicated by the observation that a
1 nM E2 treatment of -/- MCF-10A cultures upregu-
lated prolactin (PRL) gene expression by > 6-fold, while
it down-regulated progesterone receptor (PR) gene
expression by >2-fold (Table 4). Such modulation has
important implications for mammary cell differentia-
tion/proliferation and cancer development. Pituitary
prolactin levels are known to be increased due to expo-
sure to exogenous estrogens [54], promote mammary
cancer in rats and mice [55] and can activate Ras in rat
lymphoma cells [56] with recent studies linking circulat-
ing levels to breast cancer [57]. PR, as well, is known to
induce mammary epithelial cell proliferation [58,59] and
contribute to mammary tumorigenesis [58]. Similar to
our findings, suppression of PR gene expression in
human breast epithelial cells ML-20 and KPL-1 within a
hypoxic microenvironment promoted malignancy [60].
Interestingly, we noted that HC withdrawal was noted
to modulate expression of estrogen responsive genes
pS2, EBAG9, and PRL and genes involved in estrogen
signaling such as EGF, c-fos, c-jun, c-myc, and H-ras
(Table 5), which may be the result of an attempt by the
cell to combat oxidative stress-induced cellular
transformation.
The reasons for down-regulated EGF expression due
to HC withdrawal are unclear. However, the presence of
EGF inhibited MCF-10A foci formation even when cells
were continuously treated with E2 (Table 1). EGF with-
drawal was previously documented to transform human
breast epithelial cell line HMT-3522, where EGFR sup-
pression was posited to promote estrogen-responsive
breast cancer [44,45]. As well, low EGF levels present in
low serum-containing medium stimulated growth of
human breast cancer cell lines A431 and BT20, expres-
sing high ERa levels, while high EGF concentrations
inhibited cell growth [53]. Interestingly, in EGF-depleted
MCF-10A cells, increased ROS generation due to benzo
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[a]pyrene-quinone (BPQ) exposure was seen to activate
EGFR [49]. In other studies, redox regulation of ER was
also apparent, where H2O2-induced oxidative stress in
MCF-7 and T-47 D human breast cancer cells led to a
minimal upregulation of ER-a but a significant increase
in ER-b levels [61]. The initial depletion of HC and EGF
from the growth medium of MCF-10A cells could lead
to the upregulation of ER expression due to both EGF
withdrawal-mediated effects and elevated oxidative
stress. At the same time, increased oxidant levels conco-
mitant with EGF-withdrawal may also activate EGFR in
these cells. EGF hypersensitivity was already noted in
our system (Table 2).
Further support for increased ER and EGFR activities
due to increased oxidative stress and concomitant EGF
withdrawal was provided by the possible existence of a
novel, yet still highly speculative, direct association of
EGFR and ERa in MCF-10A seen to be induced and
believed to include the presence of ERb in chronic HC/
EGF-depleted MCF-10A cells (Fig. 7), which are the
most prone to transformation. A puzzling observation in
the Western blots showing this ternary complex forma-
tion is the presence of the ~200 kD band in lanes con-
taining the recombinant proteins ERa and ERb
synthesized in baculovirus-infected Sf9 cells (Fig. 7a-b;
lanes 1 & 9 and Fig. 7c-d; lanes 2 & 10). This observa-
tion can only be explained by copurification of these
recombinant proteins with contaminating host EGFR
proteins. Yet, Sf9 are insect spodoptera frugiperda cells
do not contain human EGFR. However, Sf9 cells do
contain a growth-blocking peptide receptor (GBPR) hav-
ing a tyrosine phosphorylation subunit, which can bind
human EGF, and can be detected in gels by probing
with anti-human EGFR antibody [62]. Thus, association
of GBPR with ERa or ERb during their synthesis in Sf9
cells would explain the presence of the ~200 kD band
in bands containing the recombinant proteins and
probed with their respective antibodies. Detection of the
~200 kD band in lanes containing both recombinant
ERa and ERb indicate that GBPR can associate with
both proteins, yet these bands would not cross-react
with both ERa and ERb antibodies, as seen, since only
one protein would be synthesized at a time in Sf9 cells.
The absence of a ~200 kD band in lanes containing
recombinant ERa or ERb in gels probed with EGFR
antibodies (Fig. 7e-f; lanes 1-2 & 9-10) may be due to
the fact that the EGFR moiety detected by the particular
EGFR antibody used is not present in GBPR.
Induction of this, as yet speculative, ERa/ERb/EGFR
ternary complex formation may provide an explanation
and plausible mechanism for the increased EGF and E2
sensitivity noted in the transformation of this cell line.
Chronic withdrawal of HC/EGF from MCF-10A cell cul-
tures seems to strongly facilitate the formation of this
putative ERa/ERb/EGFR ternary complex, a possible
manifestation of the ER and EGFR upregulation induced
by increased ROS and EGF deficiency in the microenvir-
onment, thereby conferring both EGF and E2 hypersen-
sitivity to cells. While work by other laboratories have
implicated either ER or EGFR upregulation/activation
due to the actions of EGF withdrawal and increased oxi-
dative stress either by themselves or together, the pre-
sent study indicates increased activation of both ER and
EGFR in the MCF-10A cell line due to the simultaneous
effects of both increased oxidant stress and EGF with-
drawal. The transformation-enhancing action of such
EGF and E2 hypersensitivity can be mediated by the
induction of this possible ERa/ERb/EGFR ternary com-
plex noted to occur under EGF-deficient, pro-oxidant
conditions. Marquez et al. have also demonstrated a
novel direct interaction between ER and EGFR after
EGF treatment of MCF-7 cells where EGFR tyrosine
kinase phosphorylates ERa at tyrosine-537 and tyrosine-
43, possibly leading to estrogen-independent activation
of ER-mediated transcription and cell proliferation
[63,64]. Others have reported similar results [65]. Pro-
teins recognized by ER-a and ER-b monoclonal antibo-
dies were found in close association to EGFR in lung
tumor cells [66]. As well, estrogen was seen to promote
an association between extranuclear ER-a and the EGFR
family member ERBB4 in the T47 D breast cancer cell
line [67]. Such cross-talk can activate diverse down-
stream signal transduction pathways which regulate cell
proliferation [66,68]. In addition, bi-directional cross
talk between ER and EGFR can enhance the individual
actions of steroids [69]. Thus, augmented cell prolifera-
tion and survival responses [14,63,70-72] due to ER/
EGFR interactions in MCF-10A cells can possibly lead
to their transformation. Several laboratories have posited
the probable co-existence and/or necessity for ER-
mediated proliferative effects and CE-mediated geno-
toxic and oxidative events in carcinogenic process
[20,73,74]. Results from the present study indicate this
to be the case in the transformation of MCF-10A cells.
Conclusions
A model for the transformation of human breast epithe-
lial cells MCF-10A (Fig. 8) is proposed where initial
chronic HC/EGF-deprivation increases ROS formation
leading to elevated oxidative stress and resultant oxida-
tive DNA damage-induced gene mutations. At the same
time, the depletion of HC and EGF induce ER upregula-
tion along with activation of EGFR leading to upregula-
tion of the postulated ERa/ERb/EGFR complex. This, in
turn, leads to enhanced ER phosphorylation by EGFR as
well as increased sensitivity to the effects of endogenous
EGF, both of which induce cell survival and/or prolifera-
tive pathways. Consequently, elevated oxidative stress
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concomitant with increased cell proliferation amplifies
replication of clones carrying DNA mutations. Further
chronic exposure of these initiated cells to E2 can again
cause increased CE-mediated ROS generation and oxida-
tive DNA damage-induced mutations. The prior upregu-
lation of ER and ER phosphorylation also enhances E2/
ER binding leading to increased cell proliferation. Simul-
taneous exposure of initiated cells to EGF also augments
EGFR activation and ER phosphorylation, again resulting
in increased cell proliferation. More pronounced oxida-
tive DNA damage and cell proliferation at this second
stage, where exogenous E2 and EGF act, significantly
raise cell transformation rates, once again due to the
increased replication of clones with DNA mutations.
Part of the cellular machinery enabling such transfor-
mation is suggested by the unique cellular interconnec-
tions we observed within cultures grown in media
conducive to transformation (Figs. 5 &6). While the
exact function of these interconnections is unknown, it
is possible that they facilitate the channeling and/or
sharing of nutrients, growth factors, etc., needed for foci
survival. The discovery of the de novo creation of actin-
based tunneling nanotubules (TNTs) which arise due to
medium deprivation and are capable of transporting
organelles between cells in different cells [75] provides
support for this type intercellular communication.
This study demonstrates that microenvironmental
manipulations, namely the simultaneous depletion of
HC and EGF from culture medium, which increase
intracellular oxidative stress, can induce transformation
in the MCF-10A cell line. We have developed a growth
protocol in which the effect of chronic, physiologically
relevant microenvironmental alterations on cellular
transformation can be examined. Each analysis of dupli-
cate or triplicate samples from single experiments pre-
sented in this study represents the culmination of
extensive prior work in the selection of optimal culture
and treatment conditions. Exposure of cells to chronic,
physiologic doses of E2 were required to effect transfor-
mation, conditions that mimic the lifetime exposure of
the human breast to endogenous estrogens which is
believed to play a part in the onset of breast cancer
[76,77]. Both E2-mediated oxidative effects and ER-
mediated events were found necessary to effect transfor-
mation. Our work provides the first indications suggest-
ing a direct association of EGFR and ERa as well as a
possible ternary association (ERa/ERb/EGFR), which is
highly induced in chronically HC/EGF-depleted MCF-
10A cells which are the most prone to transformation.
Overall, results indicate that the immediate microenvir-
onment of cells exerts powerful growth cues which ulti-
mately determine their transformation potential.
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